Inhibikase Therapeutics logo
Inhibikase Therapeutics
IKT | NASDAQ
Chart Builder DCF Calculator
$1.45
-$0.07 (-4.61%)
At close: Nov 16, 2026, 4:00 PM ET
$1.45
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

Inhibikase Therapeutics Company Profile

Company profile explained

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Key Executives

Name Position
Mark T. Iwicki Chief Executive Officer & Director
David John McIntyre Chief Financial Officer
Chadwick J. Orevillo Executive Vice President & Head of Development Operations
Christopher H. Cabell FACC President, Head of Research & Development and Chief Medical Officer
Jeffrey J. Kagy Chief Human Resources Officer
John Adams Chief Scientific Officer
Timothy J. Pigot Chief Commercial & Strategy Officer

Latest SEC Filings

Date Type Title
Oct 21, 2026 4 Filing
Oct 21, 2026 3 Filing
Oct 20, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Aug 26, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 S-8 Filing
Aug 11, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Inhibikase Therapeutics
Inhibikase Therapeutics logo
Country United States
IPO Date Dec 23, 2020
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Mark T. Iwicki

Contact Details

1000 N. West Street Wilmington, Delaware 19801 United States

Stock Details

Ticker Symbol IKT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001750149
CUSIP Number 45719W205
ISIN Number US45719W2052
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.